Three-month follow-up of Pulmonary Embolism in patients with COVID-19
Coronavirus disease 2019 (COVID-19) infection has been notable for the occurrence of pulmonary venous thrombosis, also known as immunothrombosis, in addition to classical pulmonary embolism [1]. The pathophysiology underpinning this appears more platelet-dependent and related to viral-mediated endothelial inflammation, in addition to hypercoagulability [2]. To date, treatment of confirmed pulmonary embolism (PE) has followed established (pre-COVID) venous thromboembolism (VTE) guidelines [3] but it is not known whether the subsequent clinical behaviour of COVID-associated VTE differs from outcomes reported prior to the COVID-19 pandemic.
Source: Thrombosis Research - Category: Hematology Authors: Martin B. Whyte, Rosemary Barker, Philip A. Kelly, Elisa Gonzalez, Julia Czuprynska, Raj K. Patel, Catherine Rea, Felicity Perrin, Michael Waller, Caroline Jolley, Roopen Arya, Lara N. Roberts Tags: Letter to the Editors-in-Chief Source Type: research
More News: Coronavirus | COVID-19 | Hematology | Pandemics | Pulmonary Thromboembolism | Rosemary | Thrombosis